Technological Advances in Arrhythmia Management Applied to Adults with Congenital Heart Disease

Advances in the management of children and adults with congenital heart disease (CHD) have had a major impact on long-term survival, such that the projected number of adults with CHD in Europe and North America now exceeds 3.5 million.

Coronary Artery Disease and Atherosclerotic Risk Factors in a Population-Based Study of Sudden Death

Coronary artery disease (CAD) is believed to underlie 60–80% of these deaths.

Screening Young Athletes for Diseases at Risk of Sudden Cardiac Death: Role of Stress Testing for Ventricular Arrhythmias

Preparticipation evaluation (PPE) offers the potential to prevent sudden cardiac death (SCD) in young athletes by early identification of cardiac diseases at risk of malignant ventricular arrhythmias (VA).

European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-lowering Drugs in Patients with Heart Failure

Type 2 diabetes mellitus (T2DM) is common (∼20–40%) in patients with heart failure (HF), and is associated with worse symptoms and quality of life, a greater burden of HF hospitalisation, and higher mortality rates compared to patients without T2DM.

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes

Lipoprotein (a) [Lp(a)] is a risk factor for coronary artery disease (CAD) and its related phenotypes.

Improved Outcomes of Heart Transplantation in Adults with Congenital Heart Disease Receiving Regionalized Care

Heart failure is the leading cause of premature morbidity and mortality in adults with CHD (ACHD).